Chronic hepatitis B in rheumatic diseases: issues of screening and reactivation of infection: A review
- Authors: Gridneva G.I.1, Belov B.S.1, Aronova E.S.1
-
Affiliations:
- Nasonova Research Institute of Rheumatology
- Issue: Vol 96, No 5 (2024)
- Pages: 523-530
- Section: Reviews
- URL: https://journals.rcsi.science/0040-3660/article/view/256837
- DOI: https://doi.org/10.26442/00403660.2024.05.202707
- ID: 256837
Cite item
Full Text
Abstract
Patients with rheumatic diseases infected with hepatitis B virus (HBV) are difficult to manage not only due to the presence of risk factors for the development and rapid progression of liver cirrhosis, but also due to the likelihood of reactivation of this infection. Despite the successes achieved in the fight against HBV, the virus cannot be completely defeated due to the presence of hidden forms of the disease, escaping the field of vision of a rheumatologist and an infectionist. Based on the results of the analysis of current publications, the paper presents the rationale for a complete immunological screening of patients with rheumatic diseases when prescribing antirheumatic therapy. The issues of the role of COVID-19 in the exacerbation of chronic viral hepatitis B, antiviral prevention and monitoring are discussed, the classification of antirheumatic drugs according to the risk of HBV reactivation is presented.
Full Text
##article.viewOnOriginalSite##About the authors
Galina I. Gridneva
Nasonova Research Institute of Rheumatology
Author for correspondence.
Email: gigridneva@mail.ru
ORCID iD: 0000-0002-0928-3911
кандидат мед. наук, науч. сотр. лаб. коморбидных инфекций и вакцинопрофилактики
Russian Federation, MoscowBoris S. Belov
Nasonova Research Institute of Rheumatology
Email: belovbor@yandex.ru
ORCID iD: 0000-0001-7091-2054
доктор мед. наук, зав. лаб. коморбидных инфекций и вакцинопрофилактики
Russian Federation, MoscowEvgeniia S. Aronova
Nasonova Research Institute of Rheumatology
Email: eugpozd@mail.ru
ORCID iD: 0000-0002-1833-5357
кандидат мед. наук, науч. сотр. лаб. коморбидных инфекций и вакцинопрофилактики
Russian Federation, MoscowReferences
- Aguirre A, Yazdany J. Hepatitis B Screening Before Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug Therapy: Many Roads to Improvement. J Rheumatol. 2022;49(1):1-4. doi: 10.3899/jrheum.211000
- Capkin E, Yazıcı A, Karkucak M, et al. Evaluation of hepatitis serology and frequency of viral reactivation in patients with inflammatory arthritis receiving biologic agents: a multicenter observational study. Rheumatol Int. 2023;43(3):523-31. doi: 10.1007/s00296-022-05169-2
- О Всемирном дне борьбы с вирусными гепатитами: информация Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека от 28.07.2022. Режим доступа: https://www.garant.ru/products/ipo/prime/doc/404968409/#review. Ссылка активна на 29.04.2023 [O Vsemirnom dne bor'by s virusnymi gepatitami: informatsiia Federal'noi sluzhby po nadzoru v sfere zashchity prav potrebitelei i blagopoluchiia cheloveka ot 28.07.2022. Available at: https://www.garant.ru/products/ipo/prime/doc/404968409/#review. Accessed: 29.04.2023 (in Russian)].
- Каратеев А.Е., Гонтаренко Н.В., Цурган А.В., и др. Вирусные гепатиты B и C как коморбидная патология при ревматических заболеваниях: анализ данных клиники ФГБНУ НИИР им. В.А. Насоновой за 4 года. Научно-практическая ревматология. 2016;54(3):318-23 [Karateev AE, Gontarenko NV, Tsurgan AV, et al. Viral hepatitis B and C as comorbidity in rheumatic diseases: Analysis of the data of the V.A. Nasonova Research Institute of Rheumatology Clinic over 4 years. Rheumatology Science and Practice. 2016;54(3):318-23 (in Russian)]. doi: 10.14412/1995-4484-2016-318-323
- Canzoni M, Marignani M, Sorgi ML, et al. Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy. Microorganisms. 2020;8(11). doi: 10.3390/microorganisms8111792
- Makvandi M, Noormandi Pour S, Teimoori A, et al. Frequency of Hepatitis B Markers in Systemic Lupus Erythematosus Patients in Iran. Asian Pac J Cancer Prev. 2022;23(6):1921-6. doi: 10.31557/APJCP.2022.23.6.1921
- Lo Presti A, Ceccarelli F, Dorrucci M, et al. Hepatitis B and C virus infection in patients with Systemic and Cutaneous Lupus Erythematosus. New Microbiol. 2022;45(4):296-303.
- Min Y, Wei X, Xia X, et al. Hepatitis B virus infection: An insight into the clinical connection and molecular interaction between hepatitis B virus and host extrahepatic cancer risk. Front Immunol. 2023;14:1141956. doi: 10.3389/fimmu.2023.1141956
- Ramsey SD, Unger JM, Baker LH, et al. Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices. JAMA Oncol. 2019;5(4):497-505. doi: 10.1001/jamaoncol.2018.6437
- Fragoulis GE, Nikiphorou E, Dey M, et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2023;82(6):742-53. doi: 10.1136/ard-2022-223335
- Padda IS, Bhatt R, Parmar M. Upadacitinib. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023.
- Lin TC, Hashemi N, Kim SC, et al. Practice Pattern of Hepatitis B Testing in Rheumatoid Arthritis Patients: A Cross-National Comparison Between the US and Taiwan. Arthritis Care Res (Hoboken). 2018;70(1):30-8. doi: 10.1002/acr.23241
- Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-99. doi: 10.1002/hep.29800
- Fujita M, Sugiyama M, Sato Y, et al. Hepatitis B virus reactivation in patients with rheumatoid arthritis: Analysis of the National Database of Japan. J Viral Hepat. 2018;25(11):1312-20. doi: 10.1111/jvh.12933
- Mohareb AM, Patel NJ, Fu X, et al. Screening for Hepatitis B Virus Prior to Initiating Tocilizumab and Tofacitinib in Patients With Rheumatic Diseases: A Cross-sectional Study. J Rheumatol. 2022;49(1):104-9. doi: 10.3899/jrheum.210257
- Chen YM, Yang SS, Chen DY. Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: A narrative review. J Microbiol Immunol Infect. 2019;52(1):1-8. doi: 10.1016/j.jmii.2017.10.002
- Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221-44.e3. doi: 10.1053/j.gastro.2014.10.038
- Zhou Q, Zhang Q, Wang K, et al. Anti-rheumatic drug-induced hepatitis B virus reactivation and preventive strategies for hepatocellular carcinoma. Pharmacol Res. 2022;178:106181. doi: 10.1016/j.phrs.2022.106181
- Verdelli A, Corrà A, Mariotti EB, et al. An update on the management of refractory cutaneous lupus erythematosus. Front Med (Lausanne). 2022;9:941003. doi: 10.3389/fmed.2022.941003
- Tan J, Zhou J, Zhao P, Wei J. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol. 2012;31(8):1169-75. doi: 10.1007/s10067-012-1988-2
- Kalyoncu U, Yonem O, Calguneri M, et al. Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders. Rheumatol Int. 2009;29(7):777-80. doi: 10.1007/s00296-008-0790-6
- Zingarelli S, Frassi M, Bazzani C, et al. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol. 2009;36(6):1188-94. doi: 10.3899/jrheum.081246
- Wang ST, Tseng CW, Hsu CW, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib. Int J Rheum Dis. 2021;24(11):1362-9. doi: 10.1111/1756-185X.14217
- Stasi C, Tiengo G, Sadalla S, Zignego AL. Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update. J Clin Med. 2021;10(12). doi: 10.3390/jcm10122564
- Xuan D, Yu Y, Shao L, et al. Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy – a report of long-term follow-up of serial cases and literature review. Clin Rheumatol. 2014;33(4):577-86. doi: 10.1007/s10067-013-2450-9
- Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immuno- suppressive drug therapy. Gastroenterology. 2015;148(1):215-9;quiz e16-7. doi: 10.1053/j.gastro.2014.10.039
- Zhong Z, Liao W, Dai L, et al. Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection. Ann Rheum Dis. 2022;81(4):584-91. doi: 10.1136/annrheumdis-2021-221650
- Гриднева Г.И., Белов Б.С., Аронова Е.С. Хронический вирусный гепатит В и ревматические болезни: современный взгляд на проблему. Медицинский алфавит. 2022;29:20-8 [Gridneva GI, Belov BS, Aronova ES. Chronic viral hepatitis B and rheumatic diseases: modern view on problem. Medical Alphabet. 2022;29:20-8 (in Russian)]. doi: 10.33667/2078-5631-2022-22-20-28
- Chen YM, Huang WN, Wu YD, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study. Ann Rheum Dis. 2018;77(5):780-2. doi: 10.1136/annrheumdis-2017-211322
- Harigai M, Winthrop K, Takeuchi T, et al. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD Open. 2020;6(1). doi: 10.1136/rmdopen-2019-001095
- Wu YL, Ke J, Zhang BY, Zhao D. Hepatitis B virus reactivation in rheumatoid arthritis. World J Clin Cases. 2022;10(1):12-22. doi: 10.12998/wjcc.v10.i1.12
- Lin YC, Chen YJ, Lee SW, et al. Long-Term Safety in HBsAg-Negative, HBcAb-Positive Patients with Rheumatic Diseases Receiving Maintained Steroid Therapy after Pulse Therapy. J Clin Med. 2021;10(15). doi: 10.3390/jcm10153296
- Chiu HY, Hui RC, Huang YH, et al. Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study. Acta Derm Venereol. 2018;98(9):829-34. doi: 10.2340/00015555-2989
- Kuo MH, Tseng CW, Lu MC, et al. Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment. Dig Dis Sci. 2021;66(11):4026-34. doi: 10.1007/s10620-020-06725-1
- Lin WT, Chen YM, Chen DY, et al. Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study. Lupus. 2018;27(1):66-75. doi: 10.1177/0961203317711009
- Koutsianas C, Thomas K, Vassilopoulos D. Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. Ther Adv Musculoskelet Dis. 2020;12:1759720X20912646. doi: 10.1177/1759720X20912646
- Hong X, Xiao Y, Xu L, et al. Risk of hepatitis B reactivation in HBsAg-/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis. Immun Inflamm Dis. 2023;11(2):e780. doi: 10.1002/iid3.780
- Shih CA, Chen WC. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy. World J Clin Cases. 2021;9(21):5769-81. doi: 10.12998/wjcc.v9.i21.5769
- Papatheodoridis GV, Lekakis V, Voulgaris T, et al. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion. J Hepatol. 2022;77(6):1670-89. doi: 10.1016/j.jhep.2022.07.003
- Busa S, Kavanaugh A. Drug safety evaluation of apremilast for treating psoriatic arthritis. Expert Opin Drug Saf. 2015;14(6):979-85. doi: 10.1517/14740338.2015.1031743
- Koutsianas C, Hadziyannis E, Thomas K, et al. Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents. J Viral Hepat. 2021;28(12):1710-8. doi: 10.1111/jvh.13610
- Kuo MH, Tseng CW, Lee CH, et al. Moderate Risk of Hepatitis B Virus Reactivation in HBsAg(-)/HBcAb(+) Carriers Receiving Rituximab for Rheumatoid Arthritis. Sci Rep. 2020;10(1):2456. doi: 10.1038/s41598-020-59406-4
- Lan TY, Lin YC, Tseng TC, et al. Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas. Gut Liver. 2023;17(2):288-98. doi: 10.5009/gnl210551
- Ridola L, Zullo A, Laganà B, et al. Hepatitis B (HBV) reactivation in patients receiving biologic therapy for chronic inflammatory diseases in clinical practice. Ann Ist Super Sanita. 2021;57(3):244-8. doi: 10.4415/ANN_21_03_08
- Гриднева Г.И., Белов Б.С., Аронова Е.С. Реактивация хронического гепатита В у пациентки с ревматоидным артритом. Эффективная фармакотерапия. 2023;19(9):6-11 [Gridneva GI, Belov BS, Aronova ES. Reactivation of Chronic Hepatitis B in a Patient with Rheumatoid Arthritis. Effective Pharmacotherapy. 2023;19(9):6-11 (in Russian)]. doi: 10.33978/2307-3586-2023-19-9-6-11
- Белов Б.С., Абдурахманов Д.Т. Вирус гепатита В и ревматические болезни. Научно-практическая ревматология. 2020;58(2):207-13 [Belov BS, Abdurakhmanov DT. Hepatitis B virus and rheumatic diseases. Rheumatology Science and Practice. 2020;58(2):207-13 (in Russian)]. doi: 10.14412/1995-4484-2020-207-213
- Sagnelli C, Montella L, Grimaldi P, et al. COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature. Pathogens. 2022;11(7). doi: 10.3390/pathogens11070816
- Foo H, Phan F, Bagatella M, et al. Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19. Eur J Clin Microbiol Infect Dis. 2023;42(6):799-801. doi: 10.1007/s10096-023-04599-5
- Rodríguez-Tajes S, Miralpeix A, Costa J, et al. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy. J Viral Hepat. 2021;28(1):89-94. doi: 10.1111/jvh.13410
- Spera AM. Hepatitis B virus infection reactivation in patients under immunosuppressive therapies: Pathogenesis, screening, prevention and treatment. World J Virol. 2022;11(5):275-82. doi: 10.5501/wjv.v11.i5.275
- Akiyama S, Cotter TG, Sakuraba A. Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics. World J Gastroenterol. 2021;27(19):2312-24. doi: 10.3748/wjg.v27.i19.2312
- Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021;73(7):1108-23. doi: 10.1002/art.41752
- European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection. J Hepatol. 2017;67:370-98. doi: 10.1016/j.jhep.2017.03.021
- Onorato L, Pisaturo M, Camaioni C, et al. Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases. J Clin Med. 2021;10(21). doi: 10.3390/jcm10215201
- Chen YL, Lin JZ, Mo YQ, et al. Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study. Arthritis Res Ther. 2018;20(1):81. doi: 10.1186/s13075-018-1548-5
- Ивашкин В.Т., Ющук Н.Д., Маевская М.В., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Российского общества по изучению печени по диагностике и лечению взрослых больных гепатитом В. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014;3:58-88 [Ivashkin VT, Yushchuk ND, Mayevskaya MV, et al. Clinical guidelines of the Russian gastroenterological association and the Russian society on studying of liver diseases on diagnostics and treatment of adult patients with hepatitis B. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;24(3):58-88 (in Russian)].
- Yuan C, Peng J, Xia R, et al. Reactivation of Occult Hepatitis B Virus Infection During Long-Term Entecavir Antiviral Therapy. Front Microbiol. 2022;13:865124. doi: 10.3389/fmicb.2022.865124
- Zhang L, Yang S, Yu Y, et al. Prophylactic effect of tenofovir on viral reactivation in immunocompromised pregnant women living with hepatitis B virus. Hepatol Commun. 2022;6(9):2431-40. doi: 10.1002/hep4.1994
- Alnaqbi KA, Hannawi S, Namas R, et al. Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates. Int J Rheum Dis. 2022;25(10):1107-22. doi: 10.1111/1756-185X.14406
- Bonifati C, Lora V, Graceffa D, Nosotti L. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol. 2016;22(28):6444-55. doi: 10.3748/wjg.v22.i28.6444
- Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-79. doi: 10.1038/s41584-022-00798-0